Rexahn Pharmaceuticals To Attend The Money Show November 6-8, 2008 in Washington DC
ROCKVILLE, Md.--(BUSINESS WIRE)--
Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, announced today that the Company will attend the 4th Annual Washington DC Money Show November 6-8, 2008, at the Wardman Park Marriott Hotel. The Money Show showcases over 50 of the nation's leading financial experts, presenting over 175 workshops and 15 panel discussions.
Ted Jeong, Chief Financial Officer of Rexahn Pharmaceuticals, commented, "Attending the Money Show will afford us an excellent opportunity to present our portfolio of innovative treatments for cancer, CNS disorders, sexual dysfunction and other unmet medical needs to a large audience of potential investors. We are excited to share Rexahn's latest developments and news with the scientific and the investment community."
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life. For Additional information about Rexahn visit www.rexahn.com
Safe Harbor
This press release contains statements (including projections and business trends) that are forward-looking statements. Rexahn's actual results may differ materially from the anticipated results and expectations expressed in these forward-looking statements as a result of certain risks and uncertainties, including, Rexahn's lack of profitability, its auditor's going concern qualification and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. These forward-looking statements are made as of the date hereof; Rexahn assumes no obligation to update these forward-looking statements.
Source: Rexahn Pharmaceuticals, Inc.
Released November 4, 2008